Opinion of the Transparency Council – prednisonum
At its meeting on 7 April 2025, the Transparency Council adopted opinion No. 58/2025 on the inclusion of medicinal products containing the active substance prednisonum in the scope of indications for use or dosage, or method of administration other than those specified in the Summary of Product Characteristics, i.e. myasthenia gravis; myasthenic syndrome; inflammatory myopathy; inflammatory neuropathy (except Guillain-Barré syndrome)